Historical Press Releases

2014

Soligenix Expands Pipeline with Acquisition of Phase 3-Ready Oncology Clinical Program

Princeton, NJ – September 5, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City

Princeton, NJ – September 8, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Issuance of US Patent for ThermoVax™ Technology

Princeton, NJ – September 9, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma

Princeton, NJ – September 17, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in...

Soligenix Awarded NIAID Contract Valued up to $24.7 Million for the Development of Heat Stable RiVax™ Vaccine

Princeton, NJ – September 19, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in...

Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development

Princeton, NJ – September 23, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in...

Soligenix Reports Third Quarter 2014 Financial Results, Highlighted with the Acquisition of SGX301, Synthetic Hypericin, for the Treatment of Cutaneous T-Cell Lymphoma

Princeton, NJ – November 10, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board

Princeton, NJ – November 17, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer

Princeton, NJ – December 10, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Receives $617,000 in Non-Dilutive Financing from New Jersey’s Technology Business Tax Certificate Transfer Program

Princeton, NJ – December 11, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Pricing of Public Offering of Units

Princeton, NJ – December 19, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Closing of Public Offering of Units

Princeton, NJ – December 24, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Soligenix Announces Publication of Combination Ricin/Anthrax Vaccine Data

Princeton, NJ – December 29, 2014 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the...

Show per page